|
“ Hormone Therapy and the Women’s Health Initiative: lessons we have learnt, moving forward with an evidence-based approach”
GP & HP Professional Development Activity
Professor Helena Teede and Professor Henry Burger present an update for general practitioners and health professionals on “Hormone Therapy and the Women’s Health Initiative: lessons we have learnt, moving forward with an evidence-based approach”. |
|
Professor Helena Teede
Director of Research, the Jean Hailes Foundation for Women's Health and also with the Department of Medicine Monash University and Endocrinologist.
Professor Henry Burger
Board Director, Jean Hailes Foundation for Women's Health
Prince Henry's Institute of Medical Research |
|
View the On-demand Webcast
http://jeanhailes.streamcast.com.au/1_console_hi.html
http://jeanhailes.streamcast.com.au/1_console_lo.html
Note: The Livial and Breast Cancer study referred to in this presentation has ceased. Results from the study are expected to be released late 2008.
For CPD points download and print the evaluation form, complete and fax back. Your certificate will then be sent to you. CPD applications will be processed for members of the RACGP and ACRRM.
Hormone Therapy Webcast Slides (453.00 KB)
Hormone Therapy Webcast Evaluation Form (474.50 KB)
|
Webcast Requirements
You will also need a PC or Macintosh computer with sound capabilities, Internet connection and Internet Explorer 4 or later to view this on-demand webcast presentation.
High band and low band versions are available.
Total program time 1 hour 20 minutes
Parts may be viewed separately. |
Program Outline
Part 1: Therapies for Menopausal Symptoms: Update, Professor Helena Teede (28 minutes)
Part 2: Why the Women’s Health Initiative was wrongly interpreted, Professor Henry Burger (32 minutes)
Part 3: Venous Thromboembolic Disease, Alzheimer's Disease and Hormone Therapy, Professor Helena Teede (20 minutes)
Points Available
RACGP: Allocated 3 points (Category 2 - Women's Health) in the RACGP QA&CPD Program for the 2008-2010 triennium
ACRRM: Accredited with the ACRRM PDP program for 2 points core
RANZCOG: Fellows of RANZCOG can claim 1 point per hour for educational activities under the RANZCOG CPD self-education category.
References used in Webcast
Ettinger B et al. Reduction of vertebral fracture risk in postmenopausal women with osteoporosis treated with raloxifene: results from a 3-year randomized clinical trial. Multiple Outcomes of Raloxifene Evaluation (MORE) Investigators. JAMA 1999 Aug 18;282(7):637-645. Erratum in: JAMA 1999 Dec 8;282(22):2124.
Pilote L and Hlatky MA. Attitudes of women toward hormone therapy and prevention of heart disease. Amer Heart J 1995 Jun;129:1237-8.
Chlebowski RT et al. Influence of estrogen plus progestin on breast cancer and mammography in healthy postmenopausal women: the Women's Health Initiative Randomized Trial. JAMA 2003 Jun 25;289:3243-3253.
Questions and Answers
If you have a question you would like to put to these presenters simply email:
This e-mail address is being protected from spam bots, you need JavaScript enabled to view it
and a response will be shown below (no personal details will be shown).
For further information please contact:
The Jean Hailes Foundation for Women’s Health 1800 151 441 or
email:
This e-mail address is being protected from spam bots, you need JavaScript enabled to view it
Questions and Answers from the Webcast
Note: No personal details will be shown.
Questions and Answers are not intended for the discussion or
transmission of personal and confidential medical information.
Please review our Privacy Statement.
Question |
Answer |
| Can hormone therapy increase the risk of breast cancer? |
Women who take the combined oestrogen-progestin hormone therapy for up to five years are not at significantly increased risk of breast cancer. Beyond five years there is a small increase in risk. For example, if 1,000 women are followed from age 50 to 70, approximately 45 will develop breast cancer without hormone therapy. Use of hormone therapy for more than five years is thought to lead to two more cancers (for example, 47 women). Use for 10 years increases this to about 51, and for the whole 20 years to 57, an increase in risk of 1.2 per cent. Women who take oestrogen-only hormone therapy (only possible after a hysterectomy) do not have an increased risk from breast cancer after seven years. |

Content updated July 2, 2008
|